NCT06702826 is a Phase 2 clinical trial of Cadonilimab combined with SRS in Non Small Cell Lung Cancer, sponsored by Rongrong Zhou.

Who is sponsoring NCT06702826?

NCT06702826 is sponsored by Rongrong Zhou.

What drugs are being tested in NCT06702826?

Interventions in NCT06702826: Cadonilimab combined with SRS.

What condition does NCT06702826 study?

NCT06702826 studies Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy.

Is NCT06702826 still recruiting?

NCT06702826 is currently recruiting now. Last updated 25 November 2024.

Last reviewed 2024-11-25 · How we verify

NCT06702826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

Recruiting now Phase 2 Last updated 25 November 2024

What this trial tests

Phase 2 trial testing Cadonilimab combined with SRS in Non Small Cell Lung Cancer in 20 participants. Currently enrolling.

Timeline

1 November 2024

Primary endpoint
1 November 2027

1 November 2027

Quick facts

Lead sponsor	Rongrong Zhou
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 November 2024
Primary completion	1 November 2027
Estimated completion	1 November 2027
Sites	1 location across China

Drugs / interventions tested

Cadonilimab combined with SRS — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Brain Metastases — all drugs for Brain Metastases →
Stereotactic Radiation — all drugs for Stereotactic Radiation →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Rongrong Zhou — full company profile →

Who can join

Adults 18 to 75, any sex, with Non Small Cell Lung Cancer or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results? * Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC： * Receive Cadonilimab combined with SRT for brain lesions. * Visit the hospital regularly once every 12 weeks for checkups and tests

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies - a comprehensive review.
Chen H, Li S, Yang Q, Zhou F. · · 2026 · PMID 42109678 · DOI 10.3389/fonc.2026.1821752
Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions.
Liang X, Li F, Zhang Y, Hu P, et al · · 2026 · PMID 41982689 · DOI 10.21037/tlcr-2026-1-0018
Synergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases.
Boffelli L, Fimiani C, Núñez NG, Kienzler JC. · · 2025 · PMID 41396538 · DOI 10.1007/s11060-025-05379-1

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Rongrong Zhou trials

Trials by the same sponsor.

NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06702826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rongrong Zhou
Last refreshed: 25 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06702826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing